SCHEDULE: BlackRock Boosts Amphastar Stake to 11.5%
Beneficial Ownership Report (Schedule 13G Amendment)
BlackRock, Inc. has reported an increased beneficial ownership of 11.5% in Amphastar Pharmaceuticals, Inc., holding 5,333,463 shares of common stock.
Summary
- BlackRock, Inc. filed an Amendment No. 9 to Schedule 13G, disclosing its beneficial ownership in Amphastar Pharmaceuticals, Inc.
- As of September 30, 2025, BlackRock beneficially owned 5,333,463 shares of Amphastar Pharmaceuticals, Inc. Common Stock.
- This represents 11.5% of the class of securities outstanding.
- BlackRock holds sole voting power over 5,236,473 shares and sole dispositive power over 5,333,463 shares.
- No shared voting or dispositive power was reported.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 7
Explanation: The filing indicates a significant increase in institutional ownership by BlackRock, a major asset manager, which is generally viewed as a positive signal of investor confidence in Amphastar Pharmaceuticals, Inc.
Positives
- Increased institutional ownership by a major asset manager like BlackRock can signal confidence in the company's long-term prospects.
- BlackRock's significant stake of 11.5% indicates a substantial commitment to Amphastar Pharmaceuticals, Inc.
Risks
- The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, which mitigates immediate control-related risks for current management.
Future Outlook
This filing is an ownership disclosure and does not contain forward-looking statements or guidance from Amphastar Pharmaceuticals, Inc. or BlackRock, Inc. regarding future performance or strategic direction.
Management Comments
- BlackRock, Inc. certifies that, to the best of its knowledge and belief, the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Industry Context
The pharmaceutical industry often sees significant institutional investment due to its potential for innovation, long-term growth, and defensive characteristics. BlackRock's increased stake in Amphastar Pharmaceuticals, a company focused on injectable, inhalable, and ophthalmic products, aligns with broader trends of institutional investors seeking exposure to specialized healthcare sectors.
Comparison to Industry Standards
- Institutional ownership levels vary across the pharmaceutical industry, but a 11.5% stake by a firm like BlackRock is a substantial position, often indicating a long-term investment horizon.
- Compared to other mid-cap pharmaceutical companies, a significant institutional stake can enhance market visibility and potentially attract further institutional interest, aligning with common benchmarks for investor confidence.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Policy Update | BlackRock, Inc. updated its internal Power of Attorney, revoking a previous one dated April 30, 2023, and appointing new attorneys-in-fact effective January 21, 2025, for executing ownership or control-person reporting requirements. | 01/21/2025 | This is an internal BlackRock governance update, streamlining its SEC filing processes. It has no direct impact on Amphastar Pharmaceuticals, Inc.'s corporate governance. |
Stakeholder Impact
- Shareholders: Increased institutional ownership may be perceived positively, potentially boosting investor confidence and market stability.
- Management: The filing explicitly states no intent to influence control, suggesting BlackRock's role is as a passive investor, which may provide stability for current management.
Next Steps
- Amphastar Pharmaceuticals, Inc. will continue its regular SEC reporting, including quarterly and annual financial statements.
- BlackRock, Inc. will continue to monitor its investment and file further amendments to Schedule 13G if its beneficial ownership percentage changes significantly (e.g., crosses a 1% threshold up or down) or if its investment intent changes.
Key Dates
| Date | Description |
|---|---|
| 04/30/2023 | Date of previous Power of Attorney revoked by the new one. |
| 01/21/2025 | Execution date of the current Power of Attorney for BlackRock, Inc. |
| 09/30/2025 | Date of event which required the filing of this statement (beneficial ownership threshold). |
| 10/17/2025 | Signature date of the Schedule 13G Amendment No. 9 filing. |
Recommendation
holdThis filing primarily discloses a significant increase in institutional ownership by BlackRock, Inc. in Amphastar Pharmaceuticals, Inc. While increased institutional confidence is generally a positive indicator, a Schedule 13G filing alone does not provide sufficient fundamental or operational details to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' their positions and conduct further due diligence on Amphastar's financial performance, strategic initiatives, and market conditions before making new investment decisions.
Keywords
Amphastar Pharmaceuticals, BlackRock, Schedule 13G, institutional ownership, common stock, pharmaceutical, investment, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.